Antoni Castells-rekin lankidetzan egindako argitalpenak (11)

2020

  1. Clinical and Pathological Characterization of Lynch-Like Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 368-374.e1

  2. Risk of cancer in family members of patients with lynch-like syndrome

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2018

  1. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy

    PLoS ONE, Vol. 13, Núm. 9

2017

  1. Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives

    Gastroenterology, Vol. 153, Núm. 1, pp. 106-112.e2

2015

  1. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer

    Journal of Medical Genetics, Vol. 52, Núm. 7, pp. 498-502

2013

  1. Clinical subtypes and molecular characteristics of serrated polyposis syndrome

    Clinical Gastroenterology and Hepatology, Vol. 11, Núm. 6, pp. 705-711

  2. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer

    Gut, Vol. 61, Núm. 6, pp. 865-872

2011

  1. Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome

    BMC Medical Genetics, Vol. 12

2010

  1. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome

    Journal of Molecular Diagnostics, Vol. 12, Núm. 4, pp. 498-504

2009

  1. Utility of p16 immunohistochemistry for the identification of Lynch syndrome

    Clinical Cancer Research, Vol. 15, Núm. 9, pp. 3156-3162